Another interestinganticancer drug that targets VEGF is Sunitinib (Eechoute et al., 2012), which is a tyrosine kinase inhibitor withmultiple targets, that acts on VEGF signaling by inhibiting VEGF receptors andresulting in less angiogenesis, less tumor growth and reduced metastasis (Ferrara et al., 2003). This evidence concerns the gene VEGFA and neoplasm.